Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies
Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.
